Therefore, treatment approaches in these patients depend on various clinical factors, including presence of the symptoms, possibility of significant structural disease progression, disease localization, disease volume or burden, and location of the metastatic lesion [1,4,6]
Use of glucagon-like peptide 1 receptor agonists and risk of serious renal events: Scandinavian cohort study
This episode is a call to action for patients and providers alike to rethink what subclinical really means, and to prioritize outcomes over outdated lab thresholds
Weight loss and fat-burning programs
Some patients describe noticeable changes in their eating experience during treatment (5)
Is this a technical instruction guide